89469-52-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyano-2-Methoxybenzoic acid is used as an intermediate in the synthesis of various drugs, contributing to the development of new pharmaceuticals with improved therapeutic effects.
Used in Medicinal Chemistry and Drug Discovery:
4-Cyano-2-Methoxybenzoic acid is used as a building block for the preparation of other organic compounds, facilitating the discovery of novel drug candidates with potential therapeutic benefits.
Used in Anti-Inflammatory and Analgesic Applications:
4-Cyano-2-Methoxybenzoic acid is studied for its anti-inflammatory and analgesic properties, indicating its potential use in the development of medications for pain relief and inflammation management.

Upstream product

• 773837-37-9 sodium cyanide 
• 2486-80-8 4-amino-2-methoxybenzoic acid 
• 544-92-3 copper(I) cyanide 
• 406719-76-4 methyl 4-cyano-2-methoxybenzoate 

Downstream Products

• 141853-21-6 5-(4-Cyano-2-methoxyphenyl)-1,4-dihydroimidzo<4,5-c>pyrazole 
• 141853-23-8 5-(4-Cyano-2-methoxyphenyl)-2,4-dihydro-2-methylimidazo<4,5-c>pyrazole 
• 141853-17-0 5-(4-Cyano-2-methoxyphenyl)-1,4-dihydro-1-methylimidzo<4,5-d>imidazole 
• 102361-94-4 4-Cyano-2-methoxybenzoyl chloride 
• 122455-06-5 7,7-Dimethyl-2-(2-methoxy-4-cyanophenyl)-6,7-dihydro-3H,5H-pyrrolo[2,3-f]benzimidazol-6-one 
• 1513849-41-6 methyl 4-carbamoyl-2-methoxybenzoate 
• 406719-76-4 methyl 4-cyano-2-methoxybenzoate 
• 1289570-73-5 rac-4-(((2S,3S,4S)-2-(3-chloro-2-fluorophenyl)-3-(4-chloro-2-fluorophenyl)-3-cyano-4-neopentylpyrrolidine-1-carboxamido)methyl)-2-methoxybenzoic acid 
• 1289570-74-6 4-(((2R,3R,4R)-2-(3-chloro-2-fluorophenyl)-3-(4-chloro-2-fluorophenyl)-3-cyano-4-neopentylpyrrolidine-1-carboxamido)methyl)-2-methoxybenzoic acid 
• 1289571-14-7 4-{[(imidazole-1-carbonyl)-amino]-methyl}-2-methoxy-benzoic acid methyl ester 
• 1027035-76-2 methyl 4-(aminomethyl)-2-methoxybenzoate 
• 1092844-16-0 C₁₉H₁₈N₂O₂ 
• 108288-26-2 N-(3-Amino-pyridin-4-yl)-4-cyano-2-methoxy-benzamide 
• 108288-31-9 2-(4-cyano-2-methoxyphenyl)-1H-imidazo<4,5-c>pyridine monohydrochloride 

Relevant academic research and scientific papers

Glycosyl ortho-Methoxybenzoates: Catalytically Activated Glycosyl Donors with an Easily Removable and Recyclable Leaving Group

We describe the β-ortho-methoxybenzoate as a shelf stable and practical C-1 nucleofuge for catalytic chemical glycosylation in which the benzoic acid by-product can be easily removed, reisolated, and potentially recycled after the glycosylation reaction. This new type of glycosyl donor can be efficiently activated by a range of promoters, including Bi(OTf)3, Fe(OTf)3, TMSOTf (TMS = trimethylsilyl), and triflic acid, with low (10 mol-%) catalyst loadings. The donor shows higher reactivity than analogous benzoate, p-methoxybenzoate and p-cyano-o-methoxybenzoate donors. In glycosylation reactions with o-methoxybenzoate donors, the yields of disaccharide products were good to excellent for various glycosyl acceptors, including a carbohydrate-based secondary alcohol. Furthermore, β-selective mannosylation was achieved with a Crich-type donor at 0 °C to ambient temperature, without donor preactivation. The donor was also used for the first step of a one-pot two-step glycosylation to obtain a trisaccharide; the second coupling involved activation of a thioglycoside with NIS/TMSOTf (NIS = N-iodosuccinimide). We believe that this offers a good alternative to current protocols.

New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists

Vasopressin (AVP) is a hormone that stimulates an increase in water permeability through activation of V2 receptors in the kidney. The analogue of AVP, desmopressin, has proven an effective drug for diseases where a reduction of urine output is desired. However, its peptidic nature limits its bioavailability. We report herein the discovery of potent, nonpeptidic, benzylurea derived agonists of the vasopressin V2 receptor. We describe substitutions on the benzyl group to give improvements in potency and subsequent modifications to the urea end group to provide improvements in solubility and increased oral efficacy in a rat model of diuresis. The lead compound 20e (VA106483) is reported for the first time and has been selected for clinical development.

Piperazine based inhibitors of factor xa

Novel compounds of the general formulae (I) or (II), including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds a

benzamide derivatives as oxytocin agonists and vasopressin antagonists

Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or Via receptor antagonists. Pharmaceutical compositions comprising such compounds are useful in the treatment of, inter alia, primary dysmenorrhoea.

N-acylamino acid amide compounds and intermediates for preparation thereof

The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.